If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an update on the company's platform, which combines generative AI and experimental innovation, ...

This year's report, powered by insights from the Clarivate Cortellis intelligence suite of products, highlights 11 therapies that ... IMDELLTRAtm (tarlatamab-dlle) developed by Amgen | Small-cell lung ...

Amgen has a strong product portfolio, pipeline developments, and robust financial health. Read why AMGN stock is a Strong Buy ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s shares closed yesterday at $267.10. Discover ...

A dozen wake Technical Community College students signed letters of intent on Monday to work with Amgen. Amgen is planning a $1 billion expansion in Holly Springs. “This is a really good ...